Nokdirna (Desmopressin)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that increases cyclic AMP, causing aquaporin‑2 water channels to move to the cell surface, which enhances water reabsorption and concentrates urine. It also prompts endothelial cells to release stored clotting factors.

The appropriate dose of Nokdirna is individualized by the prescribing clinician based on the patient’s specific condition, age, renal function, and response to therapy. Dosage adjustments may be needed for children, the elderly, or patients with impaired kidney function, and the prescriber will set the exact regimen.

Safety data for Nokdirna in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and discuss alternatives. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using the drug.

To request Nokdirna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nokdirna (desmopressin) is a synthetic vasopressin analog that selectively targets V2 receptors, offering a longer half‑life and fewer vasoconstrictive side effects than natural vasopressin. Compared with other antidiuretics such as chlorpropamide, desmopressin provides more predictable dosing and is available in a convenient sublingual form, though all agents share a risk of hyponatremia.

Nokdirna should be stored at room temperature, below 25 °C, in its original blister pack or container. Protect the tablets from moisture, excessive heat, and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Nokdirna is taken sublingually. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption. Dosing frequency and timing are determined by the prescriber.

The most serious risks include severe hyponatremia, which can lead to seizures, coma, or cerebral edema, and water intoxication resulting in rapid weight gain and pulmonary edema. Rarely, an allergic reaction such as rash, swelling, or anaphylaxis may occur. Prompt medical attention is required if any of these symptoms develop.

Nokdirna is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in individuals with uncontrolled hyponatremia, and in those with severe renal impairment where fluid balance cannot be monitored. Caution is also advised for patients taking interacting medications such as carbamazepine, thiazide diuretics, or NSAIDs.